Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population
Open Access
- 28 November 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 27 (4) , 766-771
- https://doi.org/10.1093/carcin/bgi295
Abstract
P53-binding protein 1 (P53BP1), a central transducer of DNA-damage signals to p53, is required for both intra-S-phase and G 2 -M checkpoints, suggesting that these two proteins may work together in the p53-mediated transcriptional activation and DNA damage-repair signaling pathways. Because the p53-binding region of 53BP1 maps to the C-terminal BRCT domains, which are homologous to those found in the breast cancer protein BRCA1, we hypothesized that genetic variation in P53BP1 and p53 may contribute to breast cancer predisposition. To test this hypothesis, we simultaneously genotyped single nucleotide polymorphisms of T-885G, Glu353Asp, and Gln1136Lys in P53BP1 and Arg72Pro in p53 in a case–control study of 404 breast cancer cases and 472 cancer-free controls. We found that the P53BP1 variant genotypes (alleles) of T-885G and Gln1136Lys were associated with a significantly increased risk of breast cancer among p53 Pro/Pro carriers (OR = 2.36, 95% CI 1.16–4.83 for −885TG/GG; OR = 2.24, 95% CI 1.15–4.37 for 1136Gln/Lys + Lys/Lys and OR = 2.82, 95% CI 1.15–6.94 for >4 variant alleles of these 3 loci). In addition, the variant genotypes of above 3 loci of P53BP1 were significantly associated with elevated risk of progesterone receptor (PR) negative breast cancer, and the T-885G and Gln1136Lys with estrogen receptor (ER) negative breast cancer. Furthermore, we found a significant gene-gene interaction between P53BP1 Gln1136Lys and p53 Arg72Pro variants in relation to breast cancer, and the OR of interaction for the presence of both P53BP1 1136Gln/Lys + Lys/Lys and p53 72Arg/Pro + Pro/Pro genotypes was 1.93 (95% CI 1.06–3.52) ( P = 0.031 for interaction). These findings indicate that the SNPs in P53BP1 and p53 jointly contribute to breast cancer risk, particularly ER (−) or PR (−) breast cancer, and the p53 Arg72Pro polymorphism may serve as a risk modifier. Further functional studies are needed to confirm our findings.Keywords
This publication has 37 references indexed in Scilit:
- The codon 72 polymorphic variants of p53 have markedly different apoptotic potentialNature Genetics, 2003
- Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structureGenes & Development, 2002
- Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1Nature Structural & Molecular Biology, 2001
- A common polymorphism acts as an intragenic modifier of mutant p53 behaviourNature Genetics, 2000
- Structure of an XRCC1 BRCT domain: a new protein-protein interaction moduleThe EMBO Journal, 1998
- Role of a p53 polymorphism in the development of human papilloma-virus-associated cancerNature, 1998
- The polyproline region of p53 is required to activate apoptosis but not growth arrestOncogene, 1997
- Identification of a novel p53 functional domain that is necessary for efficient growth suppressionProceedings of the National Academy of Sciences, 1996
- Two cellular proteins that bind to wild-type but not mutant p53.Proceedings of the National Academy of Sciences, 1994
- Clinical Implications of the p53 Tumor-Suppressor GeneNew England Journal of Medicine, 1993